Off-label use of atypical antipsychotics: an update
Maglione M, Ruelaz Maher A, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T
Record ID 32011001378
English
Authors' objectives:
Antipsychotic medications are approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia, bipolar disorder, and for some drugs, depression. We
performed a systematic review on the efficacy and safety of atypical antipsychotic drugs for use in conditions lacking FDA approval.
Authors' recommendations:
Benefits and harms vary among atypical antipsychotics for off-label usage. For symptoms associated with dementia in elderly patients, small but statistically significant benefits were observed for aripiprazole, olanzapine, and risperidone. Quetiapine was associated with benefits in the treatment of generalized anxiety disorder, and risperidone was associated with benefits in the treatment of OCD; however, adverse events were common.
Details
Project Status:
Completed
URL for project:
http://www.effectivehealthcare.ahrq.gov/ehc/products/150/778/CER43_Off-LabelAntipsychotics_20110928.pdf
Year Published:
2011
URL for published report:
http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=778&PCem=EGD
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antipsychotic Agents
- Anxiety Disorders
- Attention Deficit Disorder with Hyperactivity
- Dementia
- Depressive Disorder, Major
- Obsessive-Compulsive Disorder
- Off-Label Use
- Personality Disorders
- Schizophrenia
- Sleep Initiation and Maintenance Disorders
- Stress Disorders, Post-Traumatic
- Substance-Related Disorders
- Tourette Syndrome
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.